Vimarsana
Biggest News Aggregation in the World

Page 25 - Immunic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunic Today - Breaking & Trending Today

Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity - Vimarsana News

Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...

DGAP-News: Immunic, Inc.: Immunic to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of ECCO and Announces Blinded Baseline Characteristics of Phase 2 Trial of Vidofludimus Calcium in Ulcerative Colitis - Vimarsana News

DGAP-News: Immunic, Inc.: Immunic to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of ECCO and Announces Blinded Baseline Characteristics of Phase 2 Trial of Vidofludimus Calcium in Ulcerative Colitis

DGAP-News: Immunic, Inc. / Key word(s): Conference/Study results Immunic to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of ECCO and Announces Blinded Baseline Characteristics

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update - Vimarsana News

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update - Vimarsana News

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...

MUNIC: LAUNCH OF A CAPITAL INCREASE THROUGH A PRIVATE PLACEMENT TO SUPPORT THE COMPANY'S GROWTH - Vimarsana News

MUNIC: LAUNCH OF A CAPITAL INCREASE THROUGH A PRIVATE PLACEMENT TO SUPPORT THE COMPANY'S GROWTH

Capital increase in cash via an accelerated book building procedure for an amount of approximately €3.5 m MUNIC (Euronext Growth® Paris - FR0013462231 - ALMUN), specialist in embedded and artificial